ABVX — Abivax SA Share News
0.000.00%
Last trade - 00:00Brief: Abivax Announces Acceptance Of Phase 3 Induction Trials
Brief: Abivax Announces Presentation Of Late-Breaking Abstract For Obefazimod From Abtect Phase 3 Induction Trials At 2025 UEG Meeting
French and Benelux stocks-Factors to watch
Brief: Euronext: Quarterly Review Of CAC Family
Brief: Abivax Posts H1 Operating Loss Of EUR 93.7 Mln
Brief: Abivax Announces Pricing Of $650 Mln Public Offering Of American Depositary Shares
Brief: Abivax Temporary Trading Halt Of Its Ordinary Shares On Euronext Paris
Brief: Abivax SA Files For Offering Of Up To $400 Mln Of American Depositary Shares - SEC Filing
Brief: Abivax Announces Launch Of Public Offering
Abivax hits record high after inflammatory bowel disease drug trial data
Brief: Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress
Abivax stock jumps after clinical trial milestone
French and Benelux stocks-Factors to watch
Brief: Abivax Achieves Key Milestone In Phase 3 Abtect Trial Enrollment
Brief: Abivax Announces A Change To The Composition Of Its Board Of Directors
Brief: Abivax SA Files For Mixed Shelf Of Up To $350 Million - SEC Filing
Brief: Abivax Establishes An At-The-Market (ATM) Program On Nasdaq
Brief: Abivax Sa Says Cash And Cash Equivalents Of Eur 180.5 Million As Of September 30, 2024
Brief: Abivax Announces First Patient Enrolled In Enhance-Cd, The Phase 2B Trial Of Obefazimod In Crohn’S Disease